The pelvic floor has ligaments as well as connective tissues in the pelvis. It also supports a person’s organs including the bladder, rectum, and uterus among others. The pelvic floor muscles prevent the mentioned organs from falling off the body. They also assist the organ to function properly. Generally, a pelvic floor disorder refers to a weakened pelvic muscle as well as a tear in the connective tissue. Therefore, a damaged pelvic floor can’t function as usual by providing the needed support that your organs need. As the structure becomes weak, the general functioning of the bladder, vagina, as well as uterus can be intensely affected. There are multiple causes of pelvic floor disorders. Scientists and researchers have invested in the research. Some reasons why people, particularly women, develop pelvic floor disorders include health conditions and spinal injury. Consequently, 25 percent of women in the world suffer from these disorders. Many people struggle with urinary incontinence.
Recently, Marc Beer of Renovia Inc. moved forward with multiple products for the treatment of pelvic floor disorders. The fundraiser closed $42 million in Series B funding as well as venture debt. The Medtech company has been developing different diagnostic as well as therapeutic products with the intention of treating pelvic floor disorders such as urinary incontinence. Some of the products include researchers based on the data indicating that pelvic floor disorders affect about 250 million in the world. Leva, Renovia’s first product has also received the approval of the FDA. This implies that the recent fundraiser that was supported by Longwood Fund, a prominent investment firm that is healthcare-based and Perceptive Advisers will be forwarded toward developing as well as testing four additional therapeutic products for the same cause. There will also be a new lead generation of Leva.
Working with Likeminded Individuals
Marc Beer added that his company was thrilled to receive support from some of the world’s leading healthcare investors who also share the vision of the firm to offer better diagnosis, treat as well as improve millions of women’s lives who have been affected by pelvic floor disorders. The CEO of Renovia also added that his company is using innovative as well as proprietary sensor technologies to form a stable platform that will offer customers better and affordable treatment. Moreover, the platform will provide greater knowledge as well as the drive toward new treatment options and expertise on pelvic floor disorders and treatment. Learn more: https://renoviainc.com/leadership/
For more than 20 years, Marc Beer has been commercializing biotechnology, diagnostic as well as various device industries. That’s why in 2000, he became the head of ViaCell, a major biotechnology firm specializing in the development as well as preservation and collection of the blood stem cells of umbilical cord.